Pfizer has entered into a collaboration with Seattle Genetics to license the company’s antibody-drug conjugate (ADC) technology to develop antibodies against a single oncology target. Seattle Genetics will receive US$8 M upfront and over US$200 M in potential progress-based milestone payments, as well as royalties on worldwide net sales of any developed ADC products. Pfizer will undertake the research, development, manufacturing and commercialisation of any ADC products that it develops under the collaboration. Seattle Genetics will also receive payment for material supply and annual maintenance fees along with research support payments.